Infinity Pharmaceuticals Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Seth Tasker
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 7.4yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 5.8yrs |
Actualizaciones recientes de la dirección
No hay actualizaciones
Recent updates
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$43m |
| Dec 31 2022 | n/a | n/a | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$47m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | n/a | n/a | -US$45m |
| Sep 30 2021 | n/a | n/a | -US$44m |
| Jun 30 2021 | n/a | n/a | -US$43m |
| Mar 31 2021 | n/a | n/a | -US$41m |
| Dec 31 2020 | US$1m | US$386k | -US$40m |
| Sep 30 2020 | n/a | n/a | -US$41m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$44m |
| Dec 31 2019 | US$653k | US$368k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$19m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | n/a | n/a | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$41m |
| Dec 31 2017 | US$1m | US$320k | -US$42m |
| Sep 30 2017 | n/a | n/a | -US$57m |
| Jun 30 2017 | n/a | n/a | -US$70m |
| Mar 31 2017 | n/a | n/a | US$88k |
| Dec 31 2016 | US$404k | US$266k | -US$30m |
Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Seth es razonable en comparación con empresas de tamaño similar en el mercado German.
Compensación vs. Ingresos: La compensación de Seth ha aumentado mientras la empresa no es rentable.
CEO
Seth Tasker (44 yo)
7.4yrs
Permanencia
US$1,435,444
Compensación
Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Independent Director | 17.3yrs | US$93.08k | 0.24% € 557.4 | |
| Lead Independent Director | 11.8yrs | US$125.82k | 0.017% € 38.8 | |
| Independent Director | 5.7yrs | US$85.58k | 0.0097% € 22.7 | |
| Member of Scientific Advisory Board | 5.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.8yrs | sin datos | sin datos | |
| Independent Director | 3.8yrs | US$83.08k | 0% € 0 | |
| Member of Scientific Advisory Board | 5.8yrs | sin datos | sin datos | |
| Chairman of Scientific Advisory Board | 3.8yrs | US$759.67k | sin datos | |
| Chair of Clinical Advisory Board | no data | US$73.08k | 0.012% € 27.4 | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos |
5.8yrs
Permanencia media
71yo
Promedio de edad
Junta con experiencia: La junta directiva de I3F se considera experimentada (5.8 años de antigüedad promedio).